Resolution of persistent corneal erosion after administration of topical rebamipide

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 1403-1406

  Kashima, Tomoyuki ^a,b   Akiyama, Hideo ^a   Miura, Fumihide ^b   Kishi, Shoji ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

Author keywords

Corneal erosion; Dry eye; Mucin; Mucosta; Rebamipide; Sj gren's syndrome

Indexed keywords

ANTIBIOTIC AGENT; ARTIFICIAL TEAR; EYE DROPS; HYALURONIC ACID; REBAMIPIDE;

ADULT; ARTICLE; CASE REPORT; CAUTERIZATION; CORNEA EROSION; DRUG EFFICACY; DRUG RESPONSE; DRY EYE; EYE SURGERY; FEMALE; HUMAN; LACRIMATION; OUTCOME ASSESSMENT; SCHIRMER TEST; SJOEGREN SYNDROME; TREATMENT DURATION; TREATMENT FAILURE; VISUAL ACUITY;

EID: 84865826249     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S35122     Document Type: Article

References (33)

1. [No authors listed]. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5:75-92.
2. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res. 2004;78:379-388.
3. Gipson IK, Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol. 2003;231:1-49.
4. Fleiszig SM, Zaidi TS, Ramphal R, Pier GB. Modulation of Pseudomonas aeruginosa adherence to the corneal surface by mucus. Infect Immun. 1994;62:1799-1804.
5. Blalock TD, Spurr-Michaud SJ, Tisdale AS, et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2007;48: 4509-4518.
6. Uchida M, Tabusa F, Komatsu M, Morita S, Kanbe T, Nakagawa K. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid and related compounds. Chem Pharm Bull (Tokyo). 1985;33:3775-3786.
7. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993; 38:1441-1449.
8. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol. 1987;142:23-29.
9. Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med. 1995;18:117-123.
10. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993;43:363-366.
11. Nebiki H, Higuchi K, Arakawa T, et al. Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci. 1998;43:203S-206S.
12. Arakawa T, Kobayashi K. Quality of ulcer healing-a new concept to rank healed peptic ulcers. Gastroenterol Jpn. 1993;28 Suppl 5:158-162.
13. Higuchi K, Arakawa T, Nebiki H, et al. Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci. 1998;43:99S-106S.
14. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50 Suppl 1:S3-S11.
15. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomized, double-blind, placebo-controlled study. Drugs R D. 2003;4:19-28.
16. Ro JY, Kim JY, Kim KH. The inhibitory mechanism of rebamipide on the mediator release in the guinea pig lung mast cells activated with specific antigen-antibody reactions. Pharmacology. 2001;63:175-184.
17. Saad SY, Najjar TA, Al-Sohaibani MO. The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. Pharmacol Res. 2000;42: 81-86.
18. Hong KW, Kim KE, Rhim BY, Lee WS, Kim CD. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci. 1998;43:154S-159S.
19. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y. Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci. 2000;45:1608-1616.
20. Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004; 23:613-619.
21. Watanabe T, Higuchi K, Hamaguchi M, et al. Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils. Dig Dis Sci. 2002;47:1582-1589.
22. Rios JD, Shatos M, Urashima H, Tran H, Dartt DA. OPC-12759increases proliferation of cultured rat conjunctival goblet cells. Cornea. 2006;25: 573-581.
23. Rios JD, Shatos MA, Urashima H, Dartt DA. Effect of OPC-12759 on EGF receptor activation, p44/p42 MAPK activity, and secretion in conjunctival goblet cells. Exp Eye Res. 2008;86:629-636.
24. Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28:259-263.
25. Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci. 2002;43:1004-1011.
26. Watanabe H. Significance of mucin on the ocular surface. Cornea. 2002;21:S17-S22.
27. Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol. 1984;102:1049-1051.
28. Danjo Y, Watanabe H, Tisdale AS, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci. 1998;39: 2602-2609.
29. Aihara M, Imagawa K, Funakoshi Y, Ohmoto Y, Kikuchi M. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Dig Dis Sci. 1998;43:160S-166S.
30. Kohashi M, Ishimaru N, Arakaki R, Hayashi Y. Effective treatment with oral administration of rebamipide in a mouse model of Sjögren's syndrome. Arthritis Rheum. 2008;58:389-400.
31. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S-98S.
32. Udagawa A, Shiota G, Ichiba M, Murawaki Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38:141-146.
33. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49: 202-209.